Item 7.01 – Regulation FD Disclosure: Berholtz Agreement
and Corporate Presentation
On
January 6, 2017, the Innovus Pharmaceuticals, Inc., (the
“Company”) issued a press release announcing Mr.
Berholtz’s appointment as Executive Vice President, Corporate
Development and General Counsel, a copy of which is attached hereto
as Exhibit 99.1.
The
information in this Item 7.01, including Exhibit 99.1, is being
furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference into any filing under
the Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended, whether made before or after the date
hereof, except as expressly set forth by specific reference in such
filing.
On
January 6, 2017, the Company provided an update to its corporate
presentation. The presentation will be available on the
Company’s website at
www.innovuspharma.com
and
filed herewith as Exhibit 99.2.
The
information set forth in this Item 7.01, including Exhibit 99.2, is
being furnished pursuant to Item 7.01 and shall not be deemed
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “
Exchange
Act
”), or otherwise subject to the liabilities
of that Section, and it shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or under the Exchange Act, whether made before or after
the date hereof, except as expressly provided by specific reference
in such a filing.
By
filing this Current Report on Form 8-K and furnishing the
information in this Item 7.01, the Company makes no admission as to
the materiality of Item 7.01 in this report or the presentation
attached hereto as Exhibit 99.2. The information contained in the
presentation is summary information that is intended to be
considered in the context of the Company’s filings with the
SEC and other public announcements that the Company makes, by press
release or otherwise, from time to time. The Company undertakes no
duty or obligation to publicly update or revise the information
contained in this Item, although it may do so from time to time as
its management believes is appropriate. Any such updating may be
made through the filing of other reports or documents with the SEC,
through press releases or through other public
disclosure.
The
Company cautions you that the presentation attached hereto as
Exhibit 99.2 contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act, as amended.
Statements in the presentation that are not purely historical are
forward-looking statements including, but not limited to, the
Company’s ability to execute its business plan, obtain
regulatory approval for products under development, enter into
partnering agreements, realize revenue and pursue growth
opportunities, some of which are outside the control of the
Company. Readers and attendees are cautioned not to
place undue reliance on these forward-looking statements as actual
results could differ materially from the forward-looking statements
contained herein. Attendees are urged to read the risk factors set
forth in the Company’s most recent annual report on Form
10-K, subsequent quarterly reports filed on Form 10-Q and its most
recent SEC filings. Company disclaims any intention to
update this presentation.